

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 2, 2014

**ANTRIABIO, INC.**

(Name of registrant in its charter)

**Delaware**  
(State or jurisdiction  
of incorporation or  
organization)

**000-54495**  
(Commission File  
Number)

**27-3440894**  
(IRS Employer  
Identification No.)

890 Santa Cruz  
Menlo Park, CA 94025  
(Address of principal executive offices)

(650) 241-9330  
(Registrant's telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure.**

On April 2, 2014, AntriaBio, Inc. issued the press release attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

**Item 9.01 Financial Statements and Exhibits****EXHIBIT DESCRIPTION**

99.1 Press Release of AntriaBio, Inc. dated April 2, 2014\*

\* The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **ANTRIABIO, INC.**

DATE: April 2, 2014

By: /s/ Nevan Elam  
Nevan Elam  
Chief Executive Officer & Chairman of the  
Board

## EXHIBIT INDEX

EXHIBIT	DESCRIPTION
---------	-------------

99.1	Press Release of AntriaBio, Inc. dated April 2, 2014*
------	---

\* The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.





## ANTRIBIO, INC. ANNOUNCES \$10M MILLION PRIVATE PLACEMENT

MENLO PARK, CA – (April 2, 2014) – AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that in the first quarter of 2014 it raised \$10 million in a series of private placement transactions (collectively, the “Financing”).

The Company will be using the proceeds from the Financing for general corporate purposes including the costs associated with its clinical development program for its lead product candidate, AB101, a proprietary, microsphere insulin formulation that has the potential to be administered once per week and transform the treatment paradigm in the more than \$10 billion a year basal insulin market.

Nevan Elam, AntriaBio’s Chairman and Chief Executive Officer stated, “At the beginning of the year we committed to raise sufficient funds to execute on our clinical plans for AB101 and now we are excited to move forward with a healthy balance sheet.”

As part of the Financing, AntriaBio issued 28,063,323 units with each unit consisting of one share of the Company’s common stock priced at \$0.26 per share and one warrant to purchase a share of common stock with an exercise price of \$0.39 per share. Concurrent with this issuance, the \$2.7 million in convertible bridge notes issued by the Company in January 2014 converted into shares of common stock.

The securities sold in the Financing have not been registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. As part of the Financing, the Company has agreed to file a resale registration statement on Form S-1 with the United States Securities and Exchange Commission within 30 days of the closing of the Financing for purposes of registering the resale of the shares of common stock issued or issuable in connection with the Financing.

This notice is issued pursuant to Rule 135c under the Securities Act and does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.

### About AntriaBio, Inc.

AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.

For more information visit: [www.antrio.bio.com](http://www.antrio.bio.com).

---

**Forward-Looking Statements**

This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

**AntriaBio, Inc. Contact:**

Jenene Thomas  
Jenene Thomas Communications, LLC  
(908) 938-1475  
[Jenene@jenenethomascommunications.com](mailto:Jenene@jenenethomascommunications.com)

Source: AntriaBio, Inc.

###

---





